— Sanofi (NASDAQ: SNY) reported net loss of EUR 10 million or EUR 0.01 per share for the fourth quarter of 2019, on IFRS basis, down 103.9.% and 105% respectively, from fourth quarter of 2018.
— Business EPS, a non-GAAP measure, grew 17% at constant exchange rates to EUR 1.34.
— IFRS net sales, on a reported basis, increased 6.8% year-over-year to EUR 9.61 billion.
— Sanofi Genzyme sales rose 19.7% annually, aided by strong growth of 135% in Dupixent global sales.
— Vaccine sales increased 22%, reflecting majority of U.S. influenza vaccine shipments in Q4.
— CHC sales down 5.2%, mainly due to Zantac voluntary recall, non-core divestments and changing regulatory requirements.
— For FY20, Sanofi expects business EPS to grow about 5%, at constant exchange rates.
— SNY stock was up about 4% in the pre-market trading session.
Most Popular
Adobe (ADBE) to report Q3 earnings on Sept 12. Here’s what to expect
After delivering record-high revenues in the second quarter, Adobe Inc. (NASDAQ: ADBE) is gearing up to report third-quarter results next week. The design software maker has effectively integrated advanced AI
A look at Campbell Soup’s (CPB) expectations for fiscal year 2025
Shares of Campbell Soup Company (NASDAQ: CPB) rose over 1% on Friday. The stock has gained 21% over the past three months. The company delivered sales and earnings growth for
DOCU Earnings: DocuSign Q2 2025 profit jumps on higher revenues
DocuSign, Inc. (NASDAQ: DOCU) reported a sharp increase in adjusted earnings for the second quarter of 2025. The bottom line benefitted from a 7% increase in revenues. The eSignature service
